$LQDA

JEFFS ROGER sold $400K of LQDA (indirect holdings)

JEFFS ROGER (Chief Executive Officer) sold 6,428 indirectly-held shares of Liquidia Corp (LQDA) at $62.18 ($0.40M total) on 2026-05-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · JEFFS ROGER
Published May 28, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 8:41 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

Traders may briefly reassess sentiment around insider behavior, but the disclosure does not include new operational, financial, or regulatory information.

02

Market read

A fresh Form 4 provides a new, dated insider sale, but it is typically not a standalone catalyst for repricing fundamentals.

03

What to watch

Indirect holdings and the post-sale share count (1,041,667) may matter more than the sale size; without context on prior plans, the signal is weak.

Relevance 3/10Novelty 5/10Timing: filed 2026-05-28, transaction dated 2026-05-27

Background

The filing is an SEC Form 4 insider transaction by Liquidia’s CEO, reported as an open-market sale with a stated 10b5-1 plan.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia CEO Jeffs Roger sold 6,428 shares in an open-market transaction for about $399,712, under a 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless paired with other negative company-specific news.

Evidence & confidence

Form 4 provides a new, time-stamped transaction and confirms a pre-arranged 10b5-1 plan, which typically reduces signaling risk versus discretionary sales.

Market effects

No clear sector read-through from a single 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • Liquidia Corp

    Company whose CEO insider sale is disclosed on SEC Form 4.

  • Jeffs Roger

    CEO and director who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?

Liquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.

$LQDAHighAI 8/10

Liquidia (LQDA) Q2 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q2 2026 earnings with YUTREPIA net sales at $170.4M, up 31% QoQ. Net income was $74.7M ($0.74/diluted share). The company guided 2027 revenue to exceed $1B. R&D expenses rose 185% YoY due to L606 program costs. Management highlighted strong patient adoption and market share growth.

$LQDAMedAI 8/10

LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth

Liquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.

$LQDAMed

Liquidia Corp (LQDA): Results of Operations and Financial Condition

Liquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 · Approximately 5,900 unique patient